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Abstract
Background: Previously we have shown that a fraction of the matrix metalloproteinase-9 (MMP-9) synthesized by the
macrophage cell line THP-1 was bound to a chondroitin sulphate proteoglycan (CSPG) core protein as a reduction sensitive
heteromer. Several biochemical properties of the enzyme were changed when it was bound to the CSPG.
Methodology/Principal Findings: By use of affinity chromatography, zymography, and radioactive labelling, various
macrophage stimulators were tested for their effect on the synthesis of the proMMP-9/CSPG heteromer and its components
by THP-1 cells. Of the stimulators, only PMA largely increased the biosynthesis of the heteromer. As PMA is an activator of
PKC, we determined which PKC isoenzymes were expressed by performing RT-PCR and Western Blotting. Subsequently
specific inhibitors were used to investigate their involvement in the biosynthesis of the heteromer. Of the inhibitors, only
Rottlerin repressed the biosynthesis of proMMP-9/CSPG and its two components. Much lower concentrations of Rottlerin
were needed to reduce the amount of CSPG than what was needed to repress the synthesis of the heteromer and MMP-9.
Furthermore, Rottlerin caused a minor reduction in the activation of the PKC isoenzymes d, e, h and u (PKD3) in both control
and PMA exposed cells.
Conclusions/Significance: The biosynthesis of the proMMP-9/CSPG heteromer and proMMP-9 in THP-1 cells involves a
Rottlerin-sensitive pathway that is different from the Rottlerin sensitive pathway involved in the CSPG biosynthesis. MMP-9
and CSPGs are known to be involved in various physiological and pathological processes. Formation of complexes may
influence both the specificity and localization of the enzyme. Therefore, knowledge about biosynthetic pathways and
factors involved in the formation of the MMP-9/CSPG heteromer may contribute to insight in the heteromers biological
function as well as pointing to future targets for therapeutic agents.
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Introduction
Proteoglycans (PGs) constitute an own entity of glycoproteins,
where the core proteins are substituted with glycosaminoglycan
(GAG) chains. There are several types of GAG-chains, where
chondroitin sulphate (CS) is one of the major types. CS-chains are
unbranched and contain a variable number of negatively charged
sulphate groups which are important for their function [1,2].
Almost all mammalian cells synthesize PGs, and these are either
secreted or cell associated. PGs synthesized from monocytes and
macrophages are mainly substituted with CS-chains (CSPG) [3–7].
When monocytes are stimulated and differentiated to macro-
phages, both the biosynthesis and the secretion of CSPG are
increased [7]. The human monocyte cell line THP-1 secretes PGs
such as serglycin, versican and perlecan [8,9]. The biological role
of the secreted PGs such as serglycin from macrophages is not
clear, but it has been shown that they bind to other molecules
released from the cells through interaction with the GAG-chains,
suggesting that serglycin and other PGs may act as a kind of
carrier molecule [10,11]. It has also been reported that serglycin is
constitutively produced by multiple myeloma plasma cells and can
inhibit the bone mineralization process [12].
The family of matrix metalloproteinases (MMPs) consists of
approximately 25 different secreted and membrane-bound
mammalian enzymes. They are zinc and calcium dependent,
and together the MMPs are able to degrade most extracellular
matrix (ECM) proteins. In addition they can process and regulate
the activity of a large amount of non-ECM proteins such as growth
factors, cytokines, chemokines, cell receptors, serine proteinase
inhibitors as well as other MMPs [13–17]. Thus, MMPs have
complicated biological functions playing a role in both normal and
pathological conditions [15,18–20].
All MMPs are built up of various modules, including a pro- and
a catalytic domain. In addition, all the secreted MMPs with the
exception of the two matrilysins (MMP-7/-26) also contain a C-
terminal hemopexin-like domain [15,16]. Secreted MMPs bind to
ECM proteins, PGs as well as cell membranes [21]. The two
gelatinases MMP-2 and MMP-9 contain a unique inserted domain
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II-like repeats (FnII). This domain is similar but not identical in the
two gelatinases, and is involved in the binding of denatured
collagens, elastin and native collagen. The three FnII-like repeats
in the catalytic site of MMP-2 and MMP-9 may facilitate the
localization of these enzymes to connective tissue matrices. They
also appear to be of importance for the degradation of
macromolecules such as elastin, gelatin and collagens IV, V and
XI, but do not influence the degradation of chromogenic
substrates [22–31].
MMP-9 (92 kDa gelatinase) is produced by a variety of cell
lines, including monocytes and macrophages. MMP-9 is produced
as a monomer as well as various dimer forms [32–38]. The homo-
and several of the hetero-dimer forms are reduction sensitive.
Hence, the proteins are either covalently linked to each other
through disulfide bonds or a very strong reversible interaction
where intramolecular disulfide bonds are essential. We discovered
that THP-1 cells produced a new type of reduction sensitive
heteromer, where 10–15% of the total amount of proMMP-9
synthesized was linked to the core protein of one or several CSPGs
[38]. The binding of proMMP-9 to a CSPG alters several
biochemical properties of the enzyme [39,40]. Among these
properties are the ability to be activated by organomercurial
compounds as well as its binding to collagens and gelatins through
the three FnII repeats in the enzymes catalytic region. It was
shown that the CSPG core protein hides and prevents binding of
collagen and gelatin to the enzymes FnII domain.
The aim of the present investigation was to determine whether
different compounds known to stimulate the synthesis of proMMP-
9 and CSPGs also can increase the syntheses of proMMP-9/
CSPG heteromers in THP-1 cells, and to what extent various
PKCs are involved. Our results revealed that only PMA
significantly increased the biosynthesis of the heteromers and that
a Rottlerin sensitive pathway is involved.
Materials and Methods
Materials
Formaldehyde, TRIS, urea, DMSO and sodium acetate were
from Merck. Trichloroacetic acid (TCA), Ethanolamine and
EDTA were from Fluka. Acrylamide, Coomassie Brilliant Blue
G-250 and Triton X-100 were from BDH. Safranin O (no.S-
2255), cetylpyridinuim chloride, phorbol 12-myristate 13-acetate
(PMA), blue dextran, Hepes, Brij-35, alkaline phosphatase-
conjugated antibodies, chondroitin sulphate C, gelatin, bovine
serum albumine (BSA), LPS, Concanavalin A (ConA), Sigma Fast
Protease inhibitor cocktail tablets, primers and the Jump-
Start
TMRed TaqH PCR reaction mix were purchased from Sigma.
IL-1a and IL-1b were from R&D Systems, while PGE2
(prostaglandin E2) was from Cayman Chemicals. Proteinase free
chondroitin ABC lyase (cABC) was from Seikagaku Kogyo Co.
Gelatin-Sepharose, Q-Sepharose, Superose 6 (HR 10/30), Sepha-
dex G-50 (fine), Amplify and
14C-labeled Rainbow
TM protein
molecular weight standards were from GE-Healthcare. Ultima
Gold XR, [
35S]sulphate and [
3H]glucosamine were obtained from
Perkin Elmer. DC Protein Assay and unlabeled molecular weight
standards were from BioRad. Magic Marker molecular weight
standards and pre-casted polyacrylamide gels (NuPAGE Novex 4–
12% Bis-Tris gels) for Western blotting were from Invitrogen.
Solution cell proliferation assay (Cell Titer 96AQueous One) was
from Promega. Rabbit polyclonal antibody against human PKCa,
rabbit monoclonal antibodies against human Phospho-MAP-
KAPK-2 (Thr222) and PKCe were from Cell Signaling Technol-
ogy. Western Blotting Luminol Reagent, HRP-conjugated donkey
anti-goat secondary antibody, rabbit polyclonal antibodies against
human ERK2, PKC bI, bII, d and goat polyclonal antibody
against human PKCh were from Santa Cruz Biotechnology.
Rabbit polyclonal antibody against PKD3 was a kind gift from Dr.
Johan Van Lint, Catholic University, Leuven, Belgium. HRP-
conjugated goat anti-rabbit secondary antibody was from
Southern Biotech. MCSF (macrophage colony stimulating factor),
TNF-a, bFGF, IL-3, IL-6, Go ¨6983, Go ¨6976 and Rottlerin were
from Calbiochem. NucleoSpin RNAII kit was from Macherey-
Nagel. iScript cDNA synthesis kit and DC Protein assay kit was
from Bio-Rad. Kodak Scientific imaging film, X-OMAT AR was
from Kodak.
Biosynthesis of proMMP-9/CSPG heteromer, proMMP-9
and CSPGs
The human leukemic monocyte cell-line THP-1 was a kind gift
from Dr. K. Nilsson, Department of Pathology, Uppsala University,
Sweden. The cells were cultured in RPMI 1640 medium with 10%
fetal bovine serum, 50 mg/ml of streptomycin, and 100 units/ml of
penicillin. To investigate the effect of various biological compounds
on the biosynthesis of proMMP-9/CSPG heteromer, proMMP-9
and CSPGs, cells were washed 3 times in serum-free medium and
then cultured for 72 h in serum-free RPMI 1640 medium with or
without the following compounds; PMA (10
29–10
25 M); IL-1a
(1–200 ng/ml), IL-1b (1–200 ng/ml), IL-3 (1–200 ng/ml), IL-6
(1–200 ng/ml), LPS (1–5000 ng/ml), ConA (1–200 mM; 26–
5200 mg/ml), TNF-a (1–200 ng/ml), bFGF (1–200 ng/ml), PGE2
(1–200 ng/ml), MCSF (1–200 ng/ml). In all cases, control cells
contained the same amount of DMSO as the cells treated with the
various biological compounds. Conditioned medium was harvested
and loose cells were removed by centrifugation at 1000 rpm for
10 min. CSPG and proMMP-9/CSPG heteromers were thereafter
isolated and detected as described below. To determine proMMP-9
the enzyme was detected directly in the harvested medium by
gelatin zymography.
Preparation of cytosol and plasma membranes
Sixty million cells treated with or without PMA (10
27 M) and
Rottlerin (5 mM) were incubated in serum-free RPMI 1640
medium for 8 hr as described above. Adherent cells (PMA
treated) were scraped off and suspended in PBS. Cells were
thereafter pelleted for 10 min at 2000 rpm and re-suspended in
50 mM Tris-HCl buffer pH 8.0 containing 5 mM CaCl2 and 1x
proteinase inhibitor cocktail along with 10 mM EDTA. Cells
were homogenized with a glass homogenizer and the cytosol
fraction was separated from plasma membrane, intact cells and
organelles by centrifugation (50,000xg for 1 h). The supernatant
fraction (cytosol) was collected and the pellet was dissolved in
20 mM Tris-HCl buffer pH 7.4 containing 8.7% sucrose, 1x
proteinase inhibitor cocktail along with 10 mM EDTA and
thereafter layered on the top of a 38.5% sucrose cushion prior to
centrifugation (100,000xg, 1 h). The plasma membrane fraction
was collected from the interface, pelleted by centrifugation
(100,000xg, 1 h), and re-suspended in 50 mM Tris-HCl buffer
pH 8.0 containing 5 mM CaCl2, 1x proteinase inhibitor cocktail
along with 10 mM EDTA [41,42]. All steps were performed at
4uC. The cytosol and plasma membrane fractions were frozen
and stored at 270uC. The amount of protein in the cytosol and
membrane fractions was determined by the DC Protein assay kit
using BSA as a standard. Four independent measurements were
performed on each cytosol and membrane preparation, and the
standard deviation of the determined protein concentrations was
less than 10%.
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reaction (RT-PCR)
Total RNA was isolated using the NucleoSpin RNAII kit
according to the manufacturer’s protocol. Two mg of RNA was
reverse-transcribed using iScript cDNA synthesis kit. The primers
for PCR were: PKCa forward: 59-atccgcagtggaatgagtcctttacat-39;
PKCa reverse: 59-ttggaaggttgtttcctgtcttcagag-39; PKCbI forward:
59-ctgtggaactgactcccactg-39; PKCbI reverse: 59-atactgaagcattttggta-
tc-39;PKCbIIforward:59-gaccgatttttcacccgcca-39;PKCbIIreverse:
59-ccatctcatagagatgctcc-39; PKCc forward: 59-cacgaagtcaagagcca-
caa-39; PKCc reverse: 59-tagctatgcaggcggaactt-39; PKCd forward:
59-caactacatgagccccacct-39; PKCd reverse: 59-gaggctctctgggtgacttg-
39; PKCe forward: 59-gatgcagaaggtcactgcaa-39; PKCe reverse: 59-
gtcgtcatggaggatggact-39; PKCj forward: 59-gttatcgatgggatggatgg-
39; PKCj reverse: 59-gcaccagctctttcttcacc-39; PKCg forward: 59-
gaacagaggttcgggatcaa-39; PKCg reverse: 59-atatttccgggttggagacc-
39; PKCh forward: 59-acaaacagggctaccagtgc-39; PKCh reverse: 59-
atgccacatgcatcacactt-39;P K C i forward: 59-tacggccaggagatacaacc-
39; PKCi reverse: 59-tcggagctcccaacaatatc-39; PKCm/PKD1 for-
ward: 59-acggcactattggagattgg-39; PKCm/PKD1 reverse: 59-tgacca-
cattttctcccaca-39; PKD2 forward: 59-gccctcacggtgcactcctatc-39;
PKD2 reverse: 59-tgacaccggagtcctctgact-39; PKCu/PKD3 forward:
59-atttgtctacaagtatctctgt-39; PKCu/PKD3 reverse: 59-ctgaccaca-
tatctagggaacg-39. The PCR cycling conditions were 35 times at
94uC for 30 sec, 55–60uC for 30 sec and 72uC for 30 sec. PCR was
performed using JumpStart
TMRed TaqH PCR reaction mix. PCR
products were visualized on an ethidium bromide-stained
agarose gel.
Cell Toxicity and Viability Assays
Cell viability tests were performed in 96-well plates, where
6610
4 cells/well were incubated with increasing concentrations of
different cytokines, growth factors, lectins, lipopolysaccharides,
PMA and PKC inhibitors in 100 ml serum-free RPMI 1640 media
for 8 to 72 h. At the end of incubation, cells were washed in PBS
and then 100 ml serum-free RPMI 1640 media containing 20 mL
of 3-(4,5-dimethythizol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sul-
fophenyl)-2H-tetrazolium salt (CellTiter 96 AQueous One Solu-
tion) was added to each well and further incubated for 1 or 4 h at
37uC and then the absorbance at 490 nm was determined in a
plate reader (VersaMax
TM, Molecular Devices Corp) according to
the manufacturer’s protocol. Absorbance of control cultures
(which was not significantly altered after 72 h of incubation in
serum-free conditions) was defined as 100% and compared with
that of treated cultures. It was also determined to which extent
PMA and the PKC inhibitor Rottlerin were toxic to the cells by
using the Trypan Blue test. Briefly, 4610
5 cells were added to each
well in 12 well plates (0.6 ml/well) and incubated for 12–72 h in
the presence or absence of different concentrations of PMA and
Rottlerin. Cells were thereafter harvested, mixed with Trypan
Blue and counted in a Bu ¨rker chamber. To harvest PMA treated
cells, a rubber scraper was used to detach the cells from the well.
Biosynthetic radiolabelling of GAG-chains
To determine the effect of the various biological compounds on
the biosynthesis of CSPG, radioactive labelling was performed by
incubating 0.8610
6 cells in 1 ml with [
35S]sulphate (50 mCi/ml)
for 72 h. To determine the effect of Rottlerin in the presence and
absence of PMA (10
27 M), GAG-chains were labelled with either
50 mCi/ml of [
35S]sulphate or 10 mCi/ml of [
3H]glucosamine by
incubating 1610
6 THP-1 cells for 8 and 23 h in 0.5 ml of serum-
free RPMI 1640 medium containing 50 mg/ml of streptomycin
and 100 units/ml of penicillin. Conditioned medium and cells
were thereafter separated through centrifugation at 2000 rpm for
10 min. The cell-free conditioned medium and the obtained cell
lysates were then applied to a Sephadex G-50 column in order to
separate free [
35S]sulphate or free [
3H]glucosamine from CSPG-
labelled with [
35S]sulphate or [
3H]glucosamine. The radioactively
labelled CSPG in the media or in the purified material was
thereafter counted in a liquid scintillation spectrometer or applied
to SDS-PAGE followed by autoradiography.
Detection of PG-bound CS-chains
PG-bound CS-chains were quantified spectrophotometrically
by the Safranin O method as described previously [38].
Isolation of secreted CSPG and proMMP-9/CSPG
heteromers
Secreted PG and the proMMP-9/PG heteromers were isolated
by Q-Sepharose anion-exchange chromatography as described
previously [38].
Isolation and detection of radioactive labelled CSPG and
free CS chains
To determine the size of CSPGs isolated from Rottlerin-treated
and untreated cells, as well as CS-chains released from CSPGs, Q-
Sepharose purified [
35S]sulphate and [
3H]glucosamine labelled
CSPG were applied to a Superose 6 (HR19/30) column. The
latter column was run in 50 mM sodium acetate, 4M guanidine
and 0.15 M NaCl, pH 6.0 and markers for void (V0) and total
volume (Vt) were blue dextran and free [
35S]sulphate, respectively.
Furthermore, to determine if a size difference between the CSPGs
isolated from Rottlerin-treated and untreated cells could be
detected on SDS-PAGE,
35S-labelled CSPG (30000 cpm/well)
was subjected to SDS-PAGE using either a 4–12% gradient gel or
a 7.5% gel (as in the zymography experiments but without added
gelatin). After the electrophoresis, the gel was soaked in Amplify
and dried and [
35S]CSPG was detected with autoradiography.
Purification of proMMP-9 from the THP-1 cells
The proMMP-9 in conditioned medium from the THP-1 cells
was partly purified as described previously [39].
Chondroitin ABC lyase (cABC) treatment
The PG bound CS-chains were removed by digestion for 2 h at
37uC with 0.2–1.0 units of cABC/ml in 0.05 M Tris-HCl, pH 8.0,
containing 0.05 M sodium acetate.
Gelatin zymography
SDS-substrate PAGE was done as described previously [38]
with gels (7.5 cm 6 8.5 cm 6 0.75 mm) containing 0.1% (w/v)
gelatin in both the stacking and separating gel, 4 and 7.5% (w/v)
of polyacrylamide, respectively. Gelatinase activity was evident as
cleared (unstained) regions, and the area of these regions was
quantified by the GelBase/GelBlot
TM Pro computer program
from Ultra Violet Products.
Western immunoblotting analysis of PKC and PKD
isoforms
Immunoreactive PKC and PKD isoforms were determined by
immunoblotting of cytosol and plasma membrane preparations
subjected to SDS-PAGE (NuPAGE Novex 4–12% Bis-Tris gels)
before electroblotting to a polyvinyl difluoride (PVDF) membrane.
Cytosolic and plasma membrane preparations were obtained as
described above and a given amount of protein was loaded to the
gels. After blockage of non-specific binding sites with non-fat milk
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pH 7.4) for 1 h at room temperature, a specified amount of cytosol
and plasma membrane were incubated with antibodies against the
PKC and PKD isoforms over night at 4uC. One blot for each
PKC isoenzyme was also incubated with an antibody against
ERK2 as an additional loading control. ERK2 has been shown to
be unaffected by PMA and rottlerin [43,44] and is located both in
the cytosol and at the plasma membrane [45]. After the incubation
with primary antibodies, the PVDF membranes were washed in
TBS-T 365 min, and incubated with HRP-conjugated donkey
anti-goat secondary antibody or goat anti-rabbit secondary
antibody for 1 h and washed 365 min with TBS-T before
visualization using a Western Blotting Luminol Reagent. The
intensity of immunoblot bands was measured using a Luminescent
Image Analyzer LAS-3000 with MultiGauge software version 3.0
(Fujifilm, Tokyo, Japan).
Statistical analysis
In all cases, at least three independent cell experiments were
performed. Assays on all harvested media and cell fractions were
performed in triplicate or more (unless otherwise stated) with data
presented as mean 6 S.D., using the Student t test.
Results
Cell morphology and viability
Untreated THP-1 cells cultured on plastic had a spherical
morphology and were non-adherent. When the cells were exposed
to the tumour promoting phorbol ester PMA they became
adherent, more flattened and spread with pseudopodia. The other
compounds used did not induce the same morphological changes.
Similar observations for PMA treated THP-1 cells were previously
described by Van Ranst and coworkers [46].
Prior to examining the effect of the various compounds on the
THP-1 cells synthesis of proMMP-9/CSPG heteromer, proMMP-9
and CSPG, we determined to which extent these compounds
affected the cell viability. For this purpose two different methods
were used, the MTS and Trypan Blue exclusion test. At the
concentrations used (see methods), none of the following com-
pounds (IL-1a, IL-1b, IL-3, IL-6, PGE2, TNF-a, bFGF and LPS)
had any effect on the viability based on the MTS test. In contrast to
this, a decrease in viability was observed when the cells were
exposed to MCSF, ConA and PMA (Fig. 1A). In the case of PMA,
the Trypan Blue exclusion test verified that PMA was slightly toxic
to the cells. Four independent experiments where the THP-1 cells
werecultured inthe absenceor presenceof 10
27 M PMAfor 24, 48
and 72 h resulted in 69612, 55612 and 56614% (mean 6 SD) of
living cells in PMA exposed cultures. The percentage of dead cells
(mean 6 SD from four independent experiments) after 24, 48 and
72 h were 562, 663a n d8 65 in control cultures and 3165,
45613 and 4466 in PMA exposed cultures.
The two PKC inhibitors Go ¨6976 (25 nM) and Go ¨6983 (25 and
100 nM) had no effect on the cell viability neither in the absence
or presence of 10
27 M PMA using the MTS test (data not shown).
However, time- and dose-dependent studies with the PKC
inhibitor Rottlerin in the absence or presence of PMA showed
that Rottlerin was toxic for the cells as monitored by the MTS and
the Trypan blue exclusion tests (Figs. 1B and C)
PMA stimulates the biosynthesis of the proMMP-9/CSPG
heteromer in a time and concentration dependent
manner
PMA is known to stimulate monocytic cell lines to increase the
synthesis of MMPs [46–49]. We therefore determined to what
extent PMA could stimulate the biosynthesis of the proMMP-9/
CSPG heteromer by THP-1 cells. In several independent experi-
ments the biosynthesis of the proMMP-9/CSPG heteromers
increased with increasing PMA concentrations with a peak at
10
27 M, and thereafter decreases with increasing PMA concen-
trations (Fig. 2A).
To study the time dependency of the accumulation of the
proMMP-9/CSPG heteromer in the culture medium, cells were
cultured in the absence or presence of PMA (10
27 M) for 8 to 72 h
before the amount of proMMP-9/CSPG heteromers was
determined as described in Materials and Methods. Figure 2B
Figure 1. Cell viability in the presence of PMA, ConA, MCSF and
Rottlerin. Cell viability was detected by the MTS assay (A, B) and by
counting viable cells in a Bu ¨rker chamber (C) using the Trypan Blue
exclusion test. In (A)6 610
4 cells in serum free medium were seeded per
well in 96 well plates in the absence or presence of PMA, ConA or MCSF
at the indicated concentrations, and incubated for 72 h. In (B) and (C)
the cells were incubated with various concentrations of Rottlerin (as
indicated in the insert in c) either in the absence or presence of 10
27 M
PMA. In (B)6 610
4 cells were seeded per well in 96 well plates and in (C)
4610
5 cells were added to each well in 12 well plates (0.6 ml/well) and
incubated in serum free medium for the indicated time period. The
results presented are from a typical experiment where N=4 in (A), 3 in
(B) and 2 in (C); *p,0.05 compared to control.
doi:10.1371/journal.pone.0020616.g001
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both untreated and PMA-treated cells, and that the amount of
heteromer increased with time for at least 72 h. In other
experiments with more material loaded to the gelatin zymography
gel, it was shown that the complex could be detected already after
8 h from both untreated and PMA treated cells (data not shown).
As it was shown that the proMMP-9/CSPG heteromer
accumulated with time for at least 72 h in the PMA exposed
cells, the question arise whether it is necessary with a continuous
exposure to the phorbol ester. Cells were therefore primed with
PMA for 3 h prior to the incubation for 72 h in the absence of
PMA. In control cultures, PMA was present during the entire 72 h
period. The cells produced comparable amounts of the heteromer
whether the PMA was removed after 3 h or not (Fig. 2C).
Likewise, whether pre-incubation of the cells with PMA occurred
in serum or serum-free media had no detectable effect on the
biosynthesis of the heteromer (Fig. 2C).
PMA stimulation affected the biosynthesis of the two
components of the proMMP-9/CSPG heteromer
differently
PMA stimulation of the THP-1 cells resulted in a concentration
(Fig. 3A) and time (Fig. 3B) dependent increase of proMMP-9 in
the cell conditioned media. Likewise, the PMA induced synthesis
of proMMP-9 continued after the removal of the phorbol ester
(Fig. 3C). Whether pre-incubation of the cells with PMA occurred
in serum or serum-free media had no detectable effect on the
biosynthesis of the proMMP-9 monomer and homodimer
(Fig. 3C).
In contrast to the PMA-induced increase in proMMP-9 and
proMMP-9/CSPG synthesis, PMA reduced the amount of
[
35S]CSPG secreted into the medium in a concentration
dependent manner (Fig. 3D, upper panel). However when the
amount of secreted [
35S]CSPG was normalized against the
number of viable cells, a slight increase was observed in the PMA
exposed cell cultures (Fig. 3D, lower panel). In both untreated
and PMA treated cells, approximately 90% of the CSPG
synthesized was secreted into the culture medium. The amount
of CSPG in the culture medium increased with time in both the
untreated and PMA treated cells. After 72 h the conditioned
culture medium from control cells contained approximately 2.5
times more [
35S]CSPG than the culture medium from PMA
treated cells (Fig. 3E, upper panel). However when the amount of
CSPG was normalized against the number of viable cells, a slight
increase in [
35S]CSPG was found in the culture medium from
PMA treated cells at all time points (Fig. 3E, lower panel).
Untreated and PMA treated THP-1 cells express various
PKC mRNA isoforms
Previously it has been shown that undifferentiated THP-1 cells
express the classical PKC isoforms a and b, novel PKC isoforms d
and e and the atypical PKC f [50]. The same authors showed that
PMA changed the expression of some of these PKC isoforms. As
PMA is known to induce activation of various classical and novel
PKC isoforms [51], we have reinvestigated at the mRNA level
which isoforms are produced by THP-1 cells in the presence and
absence of PMA. This has extended the list of PKC isoforms
present in these cells. As shown in Figure 4, both untreated and
PMA treated THP-1 cells contained mRNA for classical PKC
isoforms a, bI and bII, novel PKC isoforms d, e and h, atypical
PKC f and i as well as for PKD3 (PKCu). The signals for PKC
isoforms h and c were weak, and no mRNA could be detected for
the PKC g, and the PKD isoforms 1 (PKC m) and 2 (Fig. 4). As
also shown in Figure 4, exposure to PMA did not seem to affect the
mRNA levels of the PKC isoforms in THP-1 cells.
Rottlerin blocks the biosynthesis of proMMP-9/CSPG,
proMMP-9 and CSPG
We tested to what extent inhibitors of various PKC isoforms
could block the PMA induced biosynthesis of the proMMP-9/
CSPG complex. Neither 25 nM Go ¨6976 (inhibits PKC a, b1 and
m) nor 25–100 nM Go ¨6983 (inhibits PKC a, b1, c, d and f)
affected the PMA induced biosynthesis of the proMMP-9/CSPG
complex (Fig. 5A). Furthermore, these two PKC inhibitors did not
Figure 2. Synthesis of proMMP-9/CSPG in the absence and
presence of PMA. THP-1 cells were incubated in the absence or
presence of PMA in serum free medium. Harvested medium was
thereafter applied to Q-Sepharose chromatography and the presence of
proMMP-9/CSPG was detected with gelatin zymography as described in
Materials and Methods. In (A), cells were incubated for 72 h in the
presence of various concentrations of PMA as indicated. In (B), cells
were incubated for various time periods (as indicated) in the absence or
presence of 10
27 M PMA. The samples (containing CSPG and proMMP-
9/CSPG complex) from cells not exposed to PMA were five times more
concentrated than the samples from the PMA treated cells when
applied to the gel. In (C), cells were either incubated for 72 h in the
absence (2) or presence (+)o f1 0
27 M PMA at serum free conditions, or
pre-incubated for 3 h in the absence (2) or presence (+)o f1 0
27 M PMA
and/or 10% fetal calf serum. After the pre-incubation, cells were washed
three times in PBS and thereafter incubated in serum free medium for
72 h. Arrowhead shows the border between the separating and
stacking gel, and arrows show the position of the proMMP-9/CSPG
complexes. Purified proMMP-9 was used as a standard and the position
of the 225 kDa homodimer form is shown at the left. The gels are
representative for several similar experiments.
doi:10.1371/journal.pone.0020616.g002
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mer (Fig. 5B).
In contrast to this, Rottlerin which is reported to be a specific
inhibitor of the novel PKC d and PKC h [44,52,53] blocked the
biosynthesis of both the proMMP-9/CSPG complex and the
proMMP-9 monomer (92 kDa) and homodimer (225 kDa).
Rottlerin at a concentration of 5 mM blocked the synthesis in
both the untreated and PMA treated cells (Fig. 5C and D). Since
Rottlerin is toxic when THP-1 cells were exposed to the substance
for more than 12 h (Fig. 1C), the culture medium containing
proMMP-9/CSPG heteromer and the proMMP-9 monomer/
homodimer was recovered after 12 h in these experiments.
We have previously shown that ,0.1% of the total amount of
CSPGs sythesized by the THP-1 cells are proMMP-9/CSPG
heteromers [39]. Therefore, biosynthetic labelling of the CS-
chains with either [
35S]sulphate or [
3H]glucosamine in the
absence or presence of PMA and Rottlerin will reflect the latter
compounds effect on the cells biosynthesis of CSPGs. The results
revealed that the biosynthesis of the second component of the
complex, the CSPG, was also inhibited by Rottlerin in a
concentration dependent manner. As shown in figures 6(A) and
6(B), the conditioned culture medium from cells exposed to
Rottlerin contained less amounts of the [
35S]sulphate and
[
3H]glucosamine labelled macromolecules than medium from
cells not treated with Rottlerin. This effect of Rottlerin was seen in
both the untreated and PMA treated cells. Since PGs are highly
negatively charged molecules, the radioactively labelled macro-
molecules were subjected to Q-Sepharose chromatography. As
shown in Figure 6C (upper panel), all the
35S-labelled material was
PGs as it was eluted with 0.7 M NaCl. Rottlerin did not affect the
position of the eluted material, indicating that it did not affect the
sulphate density of the GAG-chains. The use of
3H-labelled
glucosamine showed that the majority of the radioactive sugar is
incorporated in the PGs (Fig. 6C, lower panel), but a small amount
is also eluted at around 0.3 M NaCl which is most likely
hyaluronan and non-PG glycoproteins. The fractions eluted from
the Q-Sepharose column at the position of PGs (,0.7 M NaCl)
were pooled and divided in three parts. One was treated with
cABC to degrade CS-chains, another was treated with NaOH to
liberate the CS-chains from the core protein and the third part was
Figure 3. Synthesis of proMMP-9 and CSPG in the absence and presence of PMA. A–C: Typical gelatin zymographies of 20 times diluted
conditioned medium from THP-1 cells. A: Cells were incubated for 72 h in the presence of various concentrations of PMA as indicated. B: Cells were
incubated for various time periods (as indicated) in the absence or presence of 10
27 M and 10
25 M PMA. C: Cells were either incubated for 72 h in
the absence (2) or presence (+)o f1 0
27 M PMA at serum free conditions, or pre-incubated for 3 h in the absence (2) or presence (+)o f1 0
27 M PMA
and/or 10% fetal calf serum. After the pre-incubation, cells were washed three times in PBS and thereafter incubated in serum free medium for 72 h.
A–C: The position of proMMP-9 homodimer (225 kDa), monomer (92 kDa) and proMMP-2 (72 kDa) standards is indicated. D and E: Conditioned
medium from THP-1 cells incubated with [
35S]sulphate was passed over a G-50 Sepharose column in order to separate labelled macromolecules from
free [
35S]sulphate. The amount of labelled macromolecules was determined by counting the entire pass through fraction in a liquid scintillation
spectrometer. D: Cells were incubated in the absence or presence of various concentrations of PMA for 72 h as indicated and in (E) the cells were
incubated for various time periods in the absence or presence of 10
27 M PMA. (D: upper and lower panel) Results (mean 6 s.d) were normalized
against the control (without PMA). Lower panel, results were in addition normalized against the number of viable cells. E: Results (mean 6 s.d) are
presented as cpm (upper panel) and cpm/viable cells (lower panel). The results in (D) and (E) are from a typical experiment with four parallels in (D)
and three parallels in (E), where *p,0.05 compared to control without PMA.
doi:10.1371/journal.pone.0020616.g003
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column. As seen in Figures 6(D) and 6(E), cABC totally degraded
the GAG-chains to disaccharides showing that the radioactively
labelled PGs were substituted with CS-chains. Furthermore,
Rottlerin did not affect the type of GAG-chains synthesized.
However, the size of the PGs synthesized by Rottlerin exposed
cells was smaller than the PGs synthesized by the control cells.
NaOH treatment of the material shows that also the size of the
CS-chains was smaller in the Rottlerin treated material. Since free
CS-chains with a molecular size less than 15 kDa would be
expected to elute from the Q-Sepharose column at a lower NaCl
concentration than CS-chains with equal charge density but
with molecular size .20 kDa [54,55], several experiments were
performed with material from both the control and Rottlerin-
exposed cells where the CSPG had been treated or not treated
with NaOH. Figure 6F shows that the elution profile of the free
CS-chains of the Rottlerin-treated and untreated materials
superimposed on the corresponding intact PGs. In all cases, gel
filtration on a Superose 6 column revealed that the CSPG from
the Rottlerin exposed cells had a reduced size compared to the
CSPG from the untreated cells, although the reduction in size
varied from experiment to experiment. Thus, if there were some
free CS-chains in the Rottlerin-treated material it was not possible
to separate these chains from intact CSPGs by Q-Sepharose
column chromatography at least during the conditions used in the
present work. The reduced size of the CSPG from Rottlerin
exposed cells compared to CSPG from the control cells was not
detected when [
35S]CSPG was subjected to SDS-PAGE (7.5%
acrylamide) followed by autoradiography (Fig. 6F, upper panel).
Both bands appeared at the top of the separating gel at a position
that corresponded with the proMMP-9/CSPG complex seen in
gelatin zymography. However when a 4–12% gradient gel was
used, the reduced size of the CSPG from Rottlerin exposed cells
was detected in spite of the smeared bands that appear due to the
heterogenous size of the CS-chains (Fig. 6F, lower panel). In
summary, Rottlerin treatment of the THP-1 cells was followed by
a reduced synthesis of the proMMP-9/CSPG heteromer, both
Figure 4. PKC and PKD isoenzymes expressed in THP-1 cells.
RT-PCR was used to detect the PKC and PKD isoenzyme mRNA present
in cells incubated in the absence (2) or presence (+)o f1 0
-7 M PMA. To
ensure that equal amounts of cDNA has been used in samples from
control and PMA stimulated cells, rRNA was used as a standard. The
probes used are described in Materials and Methods. Ladder is a marker
with DNA fragments of known size (in bp).
doi:10.1371/journal.pone.0020616.g004
Figure 5. Effect of PKC inhibitors on THP-1 cells synthesis of proMMP-9/CSPG heteromer and proMMP-9. Shown is a typical experiment
where cells in the absence (2) and presence (+) of PMA (10
27 M) were incubated with various concentrations of the PKC inhibitors Go ¨6976 and
Go ¨6983 (A, B) and Rottlerin (C, D). In the presence of Go ¨6976 and Go ¨6983 (A, B), cells were incubated for 72 h, while in the presence of Rottlerin (C,
D) the cells were incubated for 12 h in serum free medium. To detect the effect of the PKC inhibitors on the synthesis of the proMMP-9/CSPG
heteromer (A, C), the harvested media was applied to Q-Sepharose chromatography as described in Materials and Methods prior to gelatin
zymography. To determine the effect of the inhibitors on the synthesised proMMP-9 (B, D), the harvested medium was diluted 20 times and then
applied to gelatin zymography. Arrowhead shows the border between the separating and stacking gel and the position of purified proMMP-9
monomer (92 kDa) and proMMP-9 homodimer (225 kDa) used as a standard (Std) is shown.
doi:10.1371/journal.pone.0020616.g005
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presence of 10
27 M PMA were incubated with increasing concentrations of Rottlerin for 8 h and 23 h in serum free medium containing either
[
35S]sulphate (A)o r[
3H]glucosamine (B). A typical experiment is shown, where the results (total cpm not adjusted to the amount of living cells) are
presented as mean 6 s.d. (n=2). C–F: Cells were incubated for 24 h in serum free medium containing either [
35S]sulphate or [
3H]glucosamine. C:
[
35S]sulphate and [
3H]glucosamine labelled macromolecules were applied to Q-Sepharose chromatography and the bound CSPG were eluted with a
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CSPG and its CS chains.
Rottlerin inhibits the activation of several PKC isoforms
The inhibitory effect of Rottlerin on the biosynthesis of
proMMP-9, CSPG and proMMP-9/CSPG heteromer may be
due to inhibition of PKC activation or factors downstream to
PKC. We have therefore determined the amount of PKC in the
cytosol and the plasma membrane fraction of untreated and PMA
treated THP-1 cells. To ensure equal loading, the total amount of
cytosol and membrane proteins were determined as described in
Materials and Methods. As shown in figure 7, PMA treatment of
the cells resulted in decreased amounts of the classical and the
novel PKCs in the cytosol as expected. PMA treatment resulted
also in increased amounts of some PKCs to the plasma
membranes. The presence of 5.0 mM Rottlerin resulted in a slight
decrease in the amounts of the PKC isoenzymes d, e, h and u
(PKD3; 100 kDa) bound to the plasma membranes in the PMA
treated cells (Fig. 7). In the presence of Rottlerin, the PKC
isoenzymes e and h showed a small increase in the cytosol of the
PMA treated cells. In cells not exposed to PMA, the presence of
Rottlerin resulted in a slightly increased amount of the PKC
isoenzymes d, e and h in the cytosol and a minor decrease in the
plasma membrane (Fig. 7). MAPKAPK-2 is a mitogen-activated
protein kinase expressed in THP-1 cells [56]. Because PMA also
can stimulate the activity of MAPKAPK-2 [57,58], and Rottlerin
is a potent inhibitor of MAPKAPK-2 (IC50=5.4 mM; [59]), we
examined whether PMA activated MAPKAPK-2 in THP-1 cells.
No phosphorylation of MAPKAPK-2 at Thr-222 was detected in
control cells or cell exposed to PMA, indicating that PMA did not
activate MAPKAPK-2 in these cells (data not shown).
Several factors that have an effect on either the MMP-9
or CSPG biosynthesis have no or little effect on the
biosynthesis of the proMMP-9/CSPG heteromer
In order to determine to what extent the heteromer biosynthesis
could be induced by other biological factors than PMA, we
investigated the effect of factors known to enhance MMP synthesis
in various cell lines. Neither of the investigated factors did trigger a
significant change in the synthesis of the proMMP-9/CSPG
heteromer (Fig. 8A), although most of these compounds (TNF-a,
M-CSF, IL-1a, IL-1b, IL-3, IL-6, LPS, PGE2 and ConA) caused
an increase in the biosynthesis of proMMP-9 in a concentration
dependent manner (data not shown). However, their stimulatory
effect on proMMP-9 synthesis was 5–20 times less than the effect
of PMA. No effect on the proMMP-9 synthesis was obtained with
bFGF (data not shown).
ConA reduced, whereas TNF-a, M-CSF, IL-3, IL-6 slightly
increased the [
35S]CSPG released into the culture media (Fig. 8B,
upper panel). However, when the released [
35S]CSPG was
normalized against the number of viable cells, a large increase
in the CSPG was observed (Fig. 8B, lower panel). No change in
released CSPG occurred when the cells were exposed to LPS,
bFGF, IL-1a, IL-1b or PGE2 (data not shown). Only ConA
increased cell associated [
35S]CSPG, while the other compounds
showed a decrease or no change in cell associated CSPG (Fig. 8B).
Discussion
Previously we have shown that THP-1 cells produce a reduction
sensitive complex between proMMP-9 and a CSPG core protein
which may influence the tissue localization of the enzyme [38].
The formation of the proMMP-9/CSPG complex affects several
properties of the enzyme, including activation and binding to
collagen I and gelatin [39,40]. Furthermore, we have shown that
the CSPG core protein binds to both the hemopexin domain and
the fibronectin-like repeats in the catalytic domain of the enzyme.
The latter interaction prevented the enzyme from binding directly
to collagen and gelatin [39], which is important for the gelatinases
ability to degrade gelatin [22–31]. An increasing number of studies
reveal that processing and degradation of protein and peptide
substrates by various MMPs requires that the substrates not only
interact with the active site but also regions outside the active site,
referred to as noncatalytic sites or exosites [60–62]. In addition,
the cellular and tissue localization of an individual MMP along
with available substrates in its immediate environment may either
prevent or promote disease progression [18,63–65]. With respect
to development of new drugs, it is therefore important to consider
whether an enzyme or enzyme activity represent a target or anti-
target. The development of new inhibitors against MMPs requires
knowledge of specific exosites for different substrates and whether
a given MMP forms complexes with other molecules that either
block such exosites or create new exosites that may involve both
the MMP and its binding partner. In the present study our aim
was to determine how different factors, known to affect the
synthesis of MMP-9 or CSPG, influence the formation of the
proMMP-9/CSPG complex in THP-1 cells. Knowledge of how
various factors affect the cellular synthesis of this complex and its
individual components is important for the understanding of
putative biological conditions promoting complex formation, as
well as insight in the mechanism behind the formation of the
complex.
In the present work it is shown that 10
29 to 10
27 M PMA
strongly upregulates the THP-1 cells synthesis of the proMMP-9/
CSPG heteromer and the proMMP-9 monomer and homodimer.
However, these concentrations of PMA were also associated with
some cell death. In a previous study on THP-1 cells [46] it was
shown that PMA (10
29–10
27 M) induced the synthesis of MMP-9
in a time and concentration dependent manner similar to the
observations in the present work. In contrast to our work, the
authors did not observe that PMA induced differentiation was
accompanied by any cell death. The reason for this discrepancy is
not known. The observed cell death in the present work may
suggest that the PMA induced increase in secreted proMMP-9/
CSPG, proMMP-9 and CSPG is a result of release of intracellular
stored molecules from dying cells. Several independent facts
strongly argue against this possibility. (1) THP-1 cells and other
0.15–1.5 M NaCl gradient (----) as shown in the upper graph. #, absence of Rottlerin; D, presence of 1 mM Rottlerin. D, E: Eluted CSPG from the Q-
Sepharose column was either untreated (solid line) or treated with cABC (---) or 0.5 M NaOH (
…….) prior to application on a Superose 6 gel
chromatography column as described in Material and Methods. Cont., control without Rottlerin; Rotl., presence of 1 mM Rottlerin and Fr.No., fraction
number. F:[
35S]CSPG (N) and free [
35S]CS-chains (#) from control and Rottlerin-treated cells were subjected to Q-Sepharose chromatography as in
(C). Arrow shows the elution position of shark cartilage CS. G:[
35S]Sulphate labelled CSPG (isolated from control, PMA (10
27 M) and Rottlerin treated
cells) was subjected to SDS-PAGE (upper panel: 4% stacking gel and 7.5% separating gel; lower panel: 4–12% gradient gel) followed by
autoradiography (see Materials and Methods). An equal amount of radioactivity (based on scintillation counting) was loaded to each well in order to
be able to compare the bands. Arrowhead shows the border between the separating and stacking gel and the position of molecular size markers are
shown. Small arrow shows the bottom of the application well.
doi:10.1371/journal.pone.0020616.g006
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in granules. (2) Van Ranst and coworkers [46] showed that PMA
treatment of THP-1 cells resulted in a steady state increase in
MMP-9 mRNA for at least up to 48 h corresponding to the
increase in secreted MMP-9. (3) In the present work it is shown
that only 10% of the synthesized CSPG is associated with the cells,
which confirms that CSPG is constitutively secreted in monocytes
and macrophages [7]. (4) Gelatin zymography of lysed THP-1 cells
shows a band at around 80 kDa that is approximately 100 times
more intense than the 92 kDa MMP-9 band (data not shown).
This 80 kDa band is not seen in the cell conditioned media.
Therefore, it can be concluded that the effect of PMA on the
amount of the proMMP-9/CSPG heteromer, proMMP-9 and
CSPG secreted into the conditioned medium is due to an altered
biosynthesis, which will be discussed below.
In this study we show that the proMMP-9/CSPG complex,
proMMP-9 and CSPG increases with time in the cell conditioned
media from both unstimulated and PMA stimulated THP-1 cells.
Whether PMA was removed already after three hours, or if it was
present during the entire incubation time of 72 h did not affect the
synthesis of the proMMP-9/CSPG complex and proMMP-9.
Previously it has been shown for some cell types that prolonged
Figure 7. Effect of Rottlerin on cytosolic and plasma membrane bound PKC isoenzymes. Isolated cytosol and plasma membranes from
untreated (2) or PMA and Rottlerin treated (+) THP-1 cells were subjected to Western blotting using PKC specific antibodies. The amount of total
protein loaded (PL) to each well is shown. As an additional loading control, ERK2 was used. The diagram under each blot shows the relative amounts
(mean 6s.d.) of the PKC isoenzymes in cytosol and membranes, where the results were normalised against the untreated cytosol and membrane
controls. All results are based on equal protein loading and in all cases n=2 except for PKC d and u (PKD3) where n=3. The arrowhead shows the
active PKD3 at 100 kDa, while the two bands with reduced molecular size may be truncated variants of PKD3. The position of the molecular mass
markers at 100 and 80 kDa are shown at the left. In order to show the increased level of PKC e in the cytosol from PMA treated cells (353 mg/well) in
the presence of Rottlerin compared to the absence of this compound, a largely increased developmental exposure time of the membrane in the
presence of the Luminol substrate was needed.
doi:10.1371/journal.pone.0020616.g007
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regulation of activated PKCs [66]. The present work shows that
prolonged incubation of THP-1 cells with PMA does not
necessarily down regulate the PKCs and other factors involved
in the induction of the cells synthesis of the proMMP-9/CSPG
complex and proMMP-9. As extended exposure of cells to
Rottlerin was toxic at concentrations above 5 mM, we could not
incubate the cells in the presence of this compound for more than
8 hours in order to detect any effect on the activation of PKCs.
However, this will give a reliable picture on the role of PKC
isoenzymes in the synthesis of the proMMP-9/CSPG complex and
proMMP-9 since it was sufficient to prime the cells for three hours
with PMA in order to induce a prolonged increase in the cell
synthesis of MMP-9 and its complex with CSPG.
As PMA induces activation of the classical and novel PKCs
[51,66], it can be assumed that one or several of these PKCs are
involved in the PMA induced changes in the synthesis of
proMMP-9/CSPG, proMMP-9, and CSPG by THP-1 cells. This
assumption is supported by a previous work on THP-1 cells where
it was shown that PMA induced synthesis of MMP-9 was not due
to activation of PKA or increase in intracellular calcium [46].
Treatment of the THP-1 cells with the PKC inhibitors Go ¨6976
and Go ¨6983 reveals that the PMA induced synthesis of proMMP-
9 and its complex with CSPG is independent of the PMA induced
activation of PKC a, b or d. Hence, the PMA induced synthesis is
most likely due to the activation of one or several of the PKC
isoforms e, h or u (PKD3).
Rottlerin inhibited the synthesis of the proMMP-9/CSPG
heteromer, proMMP-9 and CSPG in both the PMA treated and
untreated THP-1 cells. Previously it has been shown that Rottlerin
influences various cellular processes such as mitochondrial
respiration [67], cell growth and viability [68], cell cycle
distribution [68], generation of superoxide [69], signalling events
and cytokine production [44] as well as macropinocytosis [70].
Rottlerin has been assumed to be a specific inhibitor of the two
novel PKCs d and h [44,52,53], although this has been disputed
[59,67]. Activation of PKC is known to be associated with
phosphorylation and transfer of the activated enzyme from the
cytosol to various membrane fractions. The nature of the
membrane fraction to which an activated PKC is translocated
depends on the stimulatory conditions used [71–73]. Analysis of
both the cytosol and the plasma membrane fraction should reveal
whether or not Rottlerin inhibits the activation of a given PKC
isoform. Inhibition should result in a decreased amount of the
PKC in the plasma membrane fraction (if the activated form is
bound to this membrane fraction) and an increased amount in the
cytosol fraction. In the present study we show that under the
conditions used, 5 mM Rottlerin inhibited the synthesis of the
MMP-9/CSPG heteromer and proMMP-9. However, Rottlerin
only slightly reduced the PMA induced activation of the PKC
isoforms d, h and u (PKD3) as well as the activated forms of PKC
d, h and e in the PMA untreated THP-1 cells. Thus it is not
possible to conclude whether or to what extent these PKC
isoenzymes are involved in the PMA induced synthesis of
proMMP-9 and its complex with CSPG. Furthermore, PMA did
not cause phosphorylation/activation of MAPKAPK-2, jeopar-
dizing a role of MAPKAPK2 in PMA-triggered proMMP-9/
CSPG synthesis. Therefore, the Rottlerin sensitivity of the
synthesis of MMP-9 and its complex formation with CSPG in
both the unstimulated and PMA stimulated cells may be due to
Rottlerin acting on enzymes downstream the PKC isoforms d, h, e
and u (PKD3) and/or on an alternative PMA induced PKC
independent pathway. Indeed, Rottlerin has been demonstrated to
inhibit the enzymatic activity of several other protein kinases [43]
Figure 8. Effects of various compounds on the synthesis of
proMMP-9/CSPG and CSPG. THP-1 cells were incubated in the
absence or presence of the compounds shown in serum free medium
for 72 h. In (A), the harvested medium was applied to Q-Sepharose
chromatography and the presence of proMMP-9/CSPG was detected
with gelatin zymography as described in Materials and Methods.
Arrowhead shows the border between the separating and stacking gel
and arrow shows the position of the 300 kDa proMMP-9/CSPG
heteromer. The position of the pro-MMP-9 homodimer (225 kDa) is
shown. B: Cells were incubated with [
35S]sulphate. The harvested serum
free medium (open bars) and the lysed cell preparations (grey bars)
were passed over a G-50 Sepharose column in order to separate
labelled macromolecules from free [
35S]sulphate. The entire pass
through fraction that contains the labelled macromolecules was then
counted in a liquid scintillation spectrometer. All results (mean 6 s.d)
were normalized against the controls, i.e. the synthesis in absence of
added compounds. In lower panel with ConA and MCSF, the results
were in addition normalized against the number of viable cells. The
results in (B) are from a typical experiment with four parallels.
doi:10.1371/journal.pone.0020616.g008
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suggested to be in a PKC-independent pathway [74–77].
As for the synthesis of MMP-9, the synthesis of CSPG was
reduced in the presence of Rottlerin. However, the synthesis of
CSPG was reduced at concentrations of Rottlerin (0.5 to 1.0 mM)
that did not affect the synthesis of the MMP-9/CSPG heteromer
and proMMP-9. This suggests that the signalling pathway involved
in the synthesis of CSPG is different from the one involved in the
synthesis of the proMMP-9/CSPG heteromer and proMMP-9.
Furthermore, at least a part of the Rottlerin induced reduction in
CSPG (Figs. 6A,B) can be ascribed to the formation of PG core
proteins containing shorter CS-chains compared to untreated
controls. This was reflected in CSPG molecules with smaller
molecular mass than the CSPGs produced in the absence of
Rottlerin (Figs. 6D and E). Although the Rottlerin treated cells
produced CSPGs with shorter CS-chains, there was no significant
difference in charge density between the CSPGs from the untreated
and Rottlerin treated cells. This was demonstrated by a similar
elution profile from the Q-Sepharose column, where the CSPG
from both the Rottlerin-treated and untreated cells were eluted at
approximately 0.7 M NaCl (Fig. 6C). This suggests that Rottlerin
inhibits one or several of the enzymes involved in CS-chain
elongation and termination. In contrast to this, it appears that
Rottlerin has no effect on the enzymes involved in the glycosylation
of proMMP-9, as gelatin zymography of cell conditioned media did
not reveal active bands with lower molecular mass than 92 kDa, but
only less amounts of the 92 kDa form. There was no reduction in
the amount of proMMP-9/CSPG heteromer formed in the
presence of 1.0 mM Rottlerin compared to control (Fig. 5C). This
suggests that Rottlerin only affected the size of CS-chains bound to
the PG core proteins but had no effect on the amount or types of
core proteins produced,or at least no changes in those PGs involved
in the complex formation with proMMP-9.
PMA mimics diacylglycerol and in addition to the activation of
the classical and novel PKCs, the Raf/MEK/ERK, JNK, p38/
MAPKAPK2 and NFkB pathways can also be activated [78-81].
This results in the regulation of several genes, such as MMP-9,
TNF-a, IL-1b and PGE2 [46,50,82,83]. Several of the compounds
used like LPS, ConA, M-CSF and IL-1b are known to activate at
least one of the following regulators and transcription factors,
TNF-a,N F kB, IRAK, ERK 1/2, p38, JNK, SAPK and PGE2
[44,84–89]. Of the compounds used in the present work, PMA
induced the largest increase in the synthesis of proMMP-9 and was
the only agent that stimulated the synthesis of the proMMP-9/
CSPG complex. This suggests that the pathways induced by
TNF-a, M-CSF, IL-1a, IL-1b, IL-3, IL-6, LPS, PGE2 and ConA
alone are not sufficient to increase the synthesis of the proMMP-9/
CSPG complex in THP-1 cells. The difference in response
between PMA and the other compounds mentioned above may be
due to different types of CSPG core proteins synthesized and/or
the synthesis of other molecules which prevent proMMP-9/CSPG
complex formation. Several studies have shown a synergetic effect
between various factors such as cytokines, growth factors and
lipopolysaccharides in the regulation of MMPs [90–93]. There-
fore, it cannot be excluded that several of the compounds used in
the present study must act together in order to stimulate the
synthesis of the proMMP-9/CSPG complex.
Our previous studies have revealed that the assembly of
proMMP-9 and the core protein of one or several CSPGs must
occur either inside the cells during the synthesis or in the
extracellular microenvironment [38]. Recently we have found that
the proMMP-9/CSPG complex can be reconstituted in vitro,a n d
that the strong reduction sensitive interaction between the two
molecules was not due to a disulfide bridge between the molecules
(Malla N et al, unpublished). In all tissues, including tumours, there
is a mixture of different cell types. If the proMMP-9/CSPG
complex also can be formed in the extracellular environment,
different cell types may contribute to the formation of this complex
byproducing one orboth ofthecomponentsofthe heteromer.Thus
the presence of a given CSPG in a tissue may affect the localization
of proMMP-9. Since we previously showed the formation of the
proMMP-9/CSPG complex affects several properties of the
enzyme, including activation and binding to collagen I and gelatin
[39,40], the presence of a given CSPG in a tissue may also influence
the activation and the proteolytic capacity of the enzyme. Based on
our knowledge of MMP-9 and PGs in physiological and
pathological processes, as well as the role of exosites in substrate
cleavage [5,12,35,94–101], one can not underestimate the putative
biological role of an MMP-9/CSPG complex.
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